Key Drivers
- Solid Liquidity
- High Leverage
- Modest Margins
AIAI Summary
CNMD now looks less like a simple medtech growth name and more like a balance-sheet repair story, where the GI product exit may clean up the portfolio but the stock likely stays capped unless management can stabilize domestic sales, sustain margins, and materially reduce leverage.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Solid Liquidity
- •High Leverage
- •Modest Margins
Conmed's liquidity and cash generation are solid, but elevated leverage, modest profitability, and a high earnings multiple keep the investment case constrained.
Price Behavior
Key Price Behavior Insights:
- •Support Holding
- •Rebound Capped
- •Failed Breakout
CNMD has weakened into a range-bound setup, with $32.1-$32.7 support holding for now but $35.9-$36.9 resistance still capping rebounds.
Failed breakout from the early-June peak led to repeated pullbacks toward the low-$32 area
Sentiment & News
Key News Insights:
- •CFO Transition
- •Q2 Earnings Date
- •Advisory Continuity
CONMED is undergoing a planned CFO transition as John E. Gallagher prepares to replace Todd Garner, while the company also set its Q2 2026 earnings release and call for July 29.
The updates point to smooth leadership continuity and a routine midyear earnings event, with limited immediate operational impact implied
Similar Companies in Healthcare
Other companies in the same sector with AI ratings